Angiodroid, a biomedical company based in Bologna, Italy, has raised $7.4 million to develop and market an automatic CO2 injector for angiographic imaging. Italian Financial Service giant CDP Venture Capital SGR and French Venture Capital and Private Equity Principal ALIAD Venture Capital by Air Liquide led the grant.

As the medical industry seeks to adapt to the growing demand for more automated outpatient procedures, Angiodroid SpA has developed a unique and innovative CO2 injector that allows radiologists to automate all their interventions in a few simple steps. This is a creative way to improve patient safety and efficiency. By reducing workloads and increasing patient satisfaction, Angiodroid® will become a high-value-added product for all hospitals looking for new potential revenue streams.

According to Angiodroid founder Sebastiano Zannoli, the funds will strengthen the company's international commercial presence, form new global partnerships with distributors and MedTech firms, and support the development of Angiopulse, an IABP console for passive counterpulsation therapy.